Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

Income Statement

Follow revenue through to earnings.

Revenue

$48.47M

FY 2025 · Annual

-57.7% YoY

Operating Income

-$163.25M

FY 2025 · Annual

Net Income

-$170.37M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000114.7M48.47M
Cost of Revenue00001M
Gross Profit000114.7M47.47M
Gross Margin———100.0%97.9%
Research & Development170.27M170.92M135.3M138.49M174.09M
Selling, General & Admin45.78M47.61M38.46M36.13M37.63M
Operating Expenses216.12M218.59M183.76M174.62M210.72M
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
EBITDA(209.4M)(211.07M)(161.92M)(39.97M)(158.47M)
EBITDA Margin———-34.8%-326.9%
Operating Income(216.12M)(218.59M)(183.76M)(59.92M)(163.25M)
Operating Margin———-52.2%-336.8%
Interest Income761K1.58M2M1.78M1.97M
Interest Expense19.44M13.88M13.51M11.52M10.99M
Other Income / Expenses(17.88M)(10.79M)3.94M4.28M(7.21M)
Income Before Tax(234M)(229.38M)(179.82M)(55.64M)(170.46M)
Pre-Tax Margin———-48.5%-351.7%
Income Tax Expense000893K(88K)
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Net Margin———-49.3%-351.5%
EPS (Basic)(3.33)(2.84)(0.80)(0.25)(0.75)
EPS (Diluted)(3.33)(2.84)(1.18)(0.25)(0.75)
Weighted Avg Shares74.84M84.57M225.57M226.23M228.52M
Weighted Avg Shares (Diluted)74.84M84.57M225.57M226.23M228.52M

GOSS Earnings Waterfall · TTM

NASDAQ:GOSS · Revenue to Net Income

Key Ratios

EPS$-0.79
Gross Margin99.7%
Net Margin-328.4%
P/E Ratio-2.3
P/S Ratio31.2

Analysis

$55.5M of revenue converted into -$180.4M of net income for the selected period. Gross margin is 99.7% and net margin is -328.4%, showing how much revenue survives after costs and taxes. EPS is $-0.79, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
SC 13GSC 13G filingNov 6, 2026
SC 13D/ASC 13D/A filingOct 29, 2026

How much revenue does GOSS generate?

Gossamer Bio, Inc. (GOSS) reported $48.47M of revenue in fiscal 2025.

Is GOSS profitable?

Gossamer Bio, Inc. (GOSS) reported -$170.37M of net income, with a net margin of -351.5%.